8 years) with acute bipolar mania
receiving olanzapine (n = 47), divalproex (n = 31), or placebo (n = 16) in a pooled olanzapine clinical trials database.
Additionally, the safety and efficacy of the company's VRAYLAR was studied in a clinical trial programme in 2,700 adult patients suffering from schizophrenia or bipolar mania
Herein, we report another case of concurrent bipolar mania
and hypokalemic periodic paralysis (HPP).
For non-response in bipolar mania
, consider combining 2 mood stabilisers (e.
Agency staff posted a review of the pediatric application for Pfizer's Geodon for bipolar mania
on the agency's Web site.
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania
Recommended Dosage: For pediatric patients with bipolar mania
, recommended initial dose is 0.
This study suggests that ziprasidone may be a rapid and beneficial treatment option for bipolar mania
," he concludes.
In the schizophrenia and bipolar mania
pivotal trials, cariprazine was generally well tolerated.
Mixed specifier for bipolar mania
and depression: highlights of DSM-5 changes and implications for diagnosis and treatment in primary care.
In these clinical trials, VRAYLAR demonstrated improvement compared to placebo as measured by Young Mania Rating Scale (YMRS) total scores in patients with bipolar mania
and by Positive and Negative Syndrome Scale (PANSS) total scores in patients with schizophrenia, according to the companies.
sup] HIV positive patients with bipolar mania
might have more cognitive impairment and more immune suppression than patients with HIV-related secondary mania.
Three other bipolar diagnoses were applied to two patients each: bipolar depression, bipolar mania
, or mixed-episode bipolar disorder, David L.
The drug is already approved in the United States as a monotherapy for acute treatment of bipolar depression and mania, a monotherapy for acute and maintenance treatment of schizophrenia, and as an adjunctive therapy for acute bipolar mania
The majority of a Food and Drug Administration advisory panel agreed that the data on the atypical antipsychotic olanzapine indicated that it was effective and had an acceptable safety profile for treating two pediatric indications: schizophrenia and bipolar mania
in patients aged 13-17 years.